Medical Providers

This guidance provides recommendations for screening pregnant patients for substance use disorder (SUD) to enhance the well-being of the maternalfetal dyad.

This web page outlines policies on substance use during pregnancy, categorizing how these policies differ from state to state.

This Guide to meant to help health care teams recognize, rethink and remediate the stigma and bias of words commonly used in caring for people with the chronic disease of substance use disorder:

This resource offers background information and tips for providers on how to use person-first language and on which terms to avoid using to reduce stigma and negative bias when discussing addiction or substance use disorder with pregnant women and mothers.

This implementation guide serves to provide other medical clinics seeking to integrate maternal mental health care into obstetric and/or pediatric settings with best practices for doing so.

The Drug Free Moms and Babies (DFMB) Project is a comprehensive and integrative medical and behavioral health program for pregnant and postpartum women. The project supports healthy baby outcomes by providing prevention, early intervention, addiction treatment, and recovery support services.

MaineMOM aims to improve care for pregnant and postpartum people with opioid use disorder and their infants by integrating maternal and substance use treatment services.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.